Cytoprotection through the use of hif hydroxylase inhibitors

• US 20060251638A1
• Filed: 06/04/2004
• Published: 11/09/2006
• Est. Priority Date: 06/06/2003
• Status: Abandoned Application

• Current Assignee: FibroGen, Inc
• Original Assignee: FibroGen, Inc
• Inventors: Liu, David Y., Guenzler-Pukall, Volkmar, Seeley, Todd W., Klaus, Stephen J.
• Application Number:
  US10/554,450
• Publication Number:
  US 20060251638A1
• Time in Patent Office: Days
• US Class Current: 424/94.400
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 31/63 Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention relates to methods for conferring cytoprotection, or for inducing a cytoprotective effect, by administering a compound that inhibits HIF hydroxylase. Compounds for use in these methods are also provided.

Claims

1. A method for conferring cytoprotection on a cell, the method comprising administering to the cell an effective amount of a compound that inhibits HIF hydroxylase activity, thereby conferring cytoprotection on the cell.

3. The method of any of claims 1 and 2, wherein the administering is in vitro.

4. The method of any of claims 1 and 2, wherein the administering is in vivo.

29. The method according to any of the preceding claims, wherein the compound is selected from the group consisting of a phenanthroline;

a heterocyclic carbonyl glycine;

a quinoline-2-carboxamide;

an isoquinoline-3-carboxamide; and

an N-substituted arylsulfonylamino hydroxamic acid.

30. The method according to any of the preceding claims, wherein the compound is selected from the group consisting of 4-Oxo-1,4-dihydro-[1,10]phenanthroline-3-carboxylic acid (Compound A), 3-{[4-(3,3-Dibenzyl-ureido)-benzenesulfonyl]-[2-(4-methoxy-phenyl)-ethyl]-amino}-N-hydroxy-propionamide (Compound B), [(4-Hydroxy-7-phenylsulfanyl-isoquinoline-3-carbonyl)-amino]-acetic acid (Compound C), [(4-Hydroxy-6-phenylsulfanyl-isoquinoline-3-carbonyl)-amino]-acetic acid (Compound D), [(1-Chloro-4-hydroxy-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid (Compound E), [(1-Bromo-4-hydroxy-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid (Compound F), [(4-Hydroxy-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid (Compound G), and [(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-acetic acid (Compound H).

2. A method for inducing a cytoprotective effect in a cell, the method comprising administering to the cell an effective amount of a compound that inhibits HIF hydroxylase activity, thereby inducing the cytoprotective effect in the cell.

5. The method of claim 2, wherein the cytoprotective effect is selected from the group consisting of increased energy preservation, increased ATP preservation, increased anaerobic respiration, reduced oxygen consumption, reduced oxidative damage, increased expression of at least one factor having anti-oxidant activity, prevention or reduction of apoptosis, increased expression of at least one anti-apoptotic factor, decreased expression of at least one pro-apoptotic factor, and increased expression of at least one cytoprotective factor.

6. The method of claim 5, wherein the factor having anti-oxidant activity is selected from the group consisting of adrenomedullin, heme oxygenase-1, and HSP70.

7. The method of claim 5, wherein the anti-apoptotic factor is selected from the group consisting of adrenomedullin, heme oxygenase-1, and HSP70.

8. The method of claim 5, wherein the pro-apoptotic factor is selected from the group consisting caspase-3 and caspase-7.

9. The method of claim 5, wherein the cytoprotective factors are selected from the group consisting of erythropoietin and vascular endothelial cell growth factor.

10. A method for increasing adrenomedullin expression in a cell, the method comprising administering to the cell an effective amount of a compound that inhibits HIF hydroxylase activity, thereby increasing adrenomedullin expression in the cell.

11. A method for increasing HSP70 expression in a cell, the method comprising administering to the cell an effective amount of a compound that inhibits HIF hydroxylase activity, thereby increasing HSP70 expression in the cell.

12. A method for increasing heme oxygenase-1 expression in a cell, the method comprising administering to the cell an effective amount of a compound that inhibits HIF hydroxylase activity, thereby increasing heme oxygenase-1 expression in the cell.

13. A method for decreasing caspase expression in a cell, the method comprising administering to the cell an effective amount of a compound that inhibits HIF hydroxylase activity, thereby decreasing caspase expression in the cell.

14. The method of claim 13, wherein the caspase is selected from the group consisting of caspase-3 and caspase-7.

15. A method for preserving ATP levels in a cell, the method comprising administering to the cell an effective amount of a compound that inhibits HIF hydroxylase activity, thereby preserving ATP levels in the cell.

16. A method for reducing or preventing apoptosis in a cell, the method comprising administering to the cell an effective amount of a compound that inhibits HIF hydroxylase activity, thereby reducing or preventing apoptosis in the cell.

17. A method for increasing expression of an anti-apoptotic factor in a cell, the method comprising administering to the cell an effective amount of a compound that inhibits HIF hydroxylase activity, thereby increasing expression of the anti-apoptotic factor in the cell.

18. The method of claim 17, wherein the anti-apoptotic factor is selected from the group consisting of adrenomedullin, heme oxygenase-1, and HSP70.

19. A method for increasing expression of a factor having anti-oxidant activity in a cell, the method comprising administering to the cell an effective amount of a compound that inhibits HIF hydroxylase activity, thereby increasing expression of the factor having anti-oxidant activity in the cell.

20. The method of claim 19, wherein the factor having anti-oxidant activity is selected from the group consisting of adrenomedullin, heme oxygenase-1, and HSP70.

21. A method for reducing or preventing oxidative damage in a cell, the method comprising administering to the cell an effective amount of a compound that inhibits HIF hydroxylase activity, thereby reducing or preventing oxidative damage in the cell.

22. A method for conferring cytoprotection to a cell exposed to or at risk for exposure to stress, the method comprising administering to the cell an effective amount of a compound that inhibits HIF hydroxylase activity, thereby conferring cytoprotection to the cell.

23. The method of claim 22, wherein the stress is selected from the group consisting of nutritional imbalance, growth factor imbalance, mechanical stress, thermal stress, reduced oxygen conditions, exposure to free radicals, hypoxia, and ischemia.

24. The method of claim 22, wherein the stress is selected from the group consisting of exposure to a chemical agent, an infectious agent, a toxin, a pollutant, a drug, and radiation.

25. The method of claim 22, wherein the stress is associated with a condition selected from the group consisting of an infection, an inflammation, an immunodeficiency disorder, anaphylaxis, an autoimmune disease, cancer, a neurodegenerative disorder, an aging-associated disorder, heart disease, and cardiac injury.

26. The method of claim 25, wherein the infection is selected from the group consisting of a viral infection and a bacterial infection.

27. The method of claim 22, wherein the stress is associated with a medical procedure or treatment.

28. The method of claim 27, wherein the medical procedure or treatment is selected from the group consisting of radiation therapy, chemotherapy, and surgery.